ND Process development agreement for ATMI to supply a disposable manufacturing process for the expansion of a patient's liver cells outside the body Financial terms were not disclosed 5/10/13 Oxford BioMedica plc (Oxford, UK) Novartis AG (Basel, Switzerland) £2.5 ($3.89) Deal to manufacture clinical grade material using Oxford's LentiVector gene delivery technology and to provide certain process development services Oxford will manufacture several batches of a lentiviral vector-encoding CTL019

Atlas Venture inked corporate strategic partnership agreements with Amgen Ventures and Novartis AG

Incyte's Jakafi, partnered with Basel, Switzerland-based Novartis AG, gets credit for blazing the trail in that indication

in January, followed by approval in the European Union, where the product is marketed by the Alcon unit of Novartis AG, of Basel, Switzerland

Atlas Venture inked corporate strategic partnership agreements with Amgen Inc., of Thousand Oaks, Calif., through its venture capital fund, Amgen Ventures, and Novartis AG, of Basel, Switzerland

Pearl reported Phase IIb results in 2011 that showed a statistically significant improvement in FEV1 of 47 percent over Foradil (formoterol, Novartis AG) and 49 percent over Spiriva (tiotroprium, Pfizer Inc./Boehringer Ingelheim GmbH) after one week of dosing (p < 0.0001 for both comparisons

They include Tudorza Pressair (aclidinium bromide inhalation powder, Forest Laboratories Inc. and Almirall SA), given the FDA's nod last summer, and Arcapta Neohaler (indacaterol maleate, Novartis AG), approved in 2011

Novartis Pharmaceuticals Corp., of East Hanover, N.J., part of Novartis AG, said the FDA approved the anti-interleukin antibody Ilaris (canakinumab) to treat active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years and older

Array BioPharma Inc., a biotech known for its drug discovery engine, is expanding its capabilities, starting its first Phase III clinical trial for MEK 162. (See BioWorld Today, May 8, 2013.) As part of its partnership with Novartis AG to develop the MEK inhibitor, Array retained co-development rights, which allows it to run clinical trials to further the development of the compound

The findings appeared in the May 8, 2013, issue of Cell Metabolism. (See BioWorld Today, March 27, 2013.) Cancer Drug Fights Neurodegeneration Very low doses of chronic myelogenous leukemia (CML) drug Tasigna (nilotinib, Novartis AG) may be a way to treat neurodegenerative disorders that are characterized by toxic protein accumulations, scientists from Georgetown University have discovered

Its lead program, RPC1063, is a sphingosine 1-phosphate receptor (S1PC) modulater that the company hopes will be competitive with Gilenya (fingolimod), the oral MS drug sold by Novartis AG

Oxford BioMedica plc, of Oxford, UK, signed an agreement with Novartis AG, of Basel, Switzerland, to manufacture clinical grade material using Oxford BioMedica's LentiVector gene delivery technology and to provide certain process development services

Array BioPharma Inc.'s Phase III trial planned for this summer in recurrent low-grade serous ovarian cancer (LGSOC) with its Novartis AG-partnered MEK inhibitor is one of a handful of late-stage studies expected to roll out this year

BIO said it shares many of the USTR's concerns over the decision by India's Supreme Court to deny patent protection for for the cancer drug Gleevec/Glivec, developed by Novartis AG, of Basel, Switzerland, on the grounds that the compound did not demonstrate "enhanced efficacy

Oxford BioMedica plc signed a manufacturing agreement with Novartis AG for clinical grade material

Novartis AG (Basel, Switzerland) $25 For the start of a Phase II trial testing c-MET inhibitor INC280 as monotherapy in patients with advanced hepatocellular carcinoma 4/30/13 Isis Pharmaceuticals Inc. (Carlsbad, Calif.) Biogen Idec Inc. (Weston, Mass.) $3.5 For the start of a Phase II study of ISIS-SMNRx in infants with spinal muscular atrophy

by partner Novartis AG, of Basel, Switzerland, totaling $5.9 million

Oxford BioMedica plc, of Oxford, UK, signed an agreement with Novartis AG, of Basel, Switzerland, to manufacture clinical grade material using Oxford BioMedica's LentiVector gene delivery technology and to provide certain process development services